No Data
No Data
Bionano Announces Publication Of A Breast Cancer Study Showing That The Number Of SVs Detected With OGM May Be Related To Prognosis, Tumor Progression And Chemotherapy Resistance
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome showing that when tumors exhibit
BioNano Genomics (BNGO) Gets a Hold From Maxim Group
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2023 Earnings Call Transcript
Bionano Genomics Is Maintained at Sector Outperform by Scotiabank
Bionano Genomics Is Maintained at Sector Outperform by Scotiabank
Express News | Scotiabank Maintains Sector Outperform on Bionano Genomics, Lowers Price Target to $6
Bionano Genomics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/07/2024 395.87% Scotiabank $7 → $6 Maintains Sector Outperform 11/13/2023 — Maxim Group Downgrades Buy
No Data